IB期非小细胞肺癌术后辅助化疗疗效的系统回顾与Meta分析

doi:10.19739/j.cnki.issn1001-9510.2019.04.013

Abstract
Figure/Table
References
Related Citation (6)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective We systematically reviewed the literature to investigate the effect of postoperative adjuvant chemotherapy in patients with completely resected stage IB non-small-cell lung cancer. Methods Pubmed, Embase, Cochrane Library and Web of Science were searched regarding the effect of postoperative adjuvant chemotherapy for completely resected stage IB non-small-cell lung cancer,and randomized controlled trials(RCT) were collected according to the inclusion criterias. Data were analysed with RevMan 5.3 software. Results Six studies with 1 286 patients were included. Pooled analysis suggested that 5-year overall survival between the two groups was similar, and the difference had no statistical significance (HR: 0.83,95% CI: 0.66~1.04,P=0.11). However, the subgroup analysis demonstrated that 5-year overall survival had statistical significance for patients who had tumors ≥ 4 cm in diameter (HR: 0.51,95% CI: 0.26~0.99,P=0.05). The 5-year disease-free survival in the adjuvant chemotherapy group was greater than the control group(HR: 0.58, 95% CI: 0.35~0.94,P=0.03). Conclusion Postoperative adjuvant chemotherapy can’t increase 5-year overall survival in patients with stage IB non-small-cell lung cancer. However, postoperative adjuvant chemotherapy can increase 5-year overall survival and 5-year disease-free survival for patients who had tumors ≥ 4 cm in diameter.

Key words： stage IB non-small-cell lung cancer surgery adjuvant chemotherapy meta-analysis

Received: 06 October 2018

PACS:

R734.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	JIA Teng
	GU Xiaojie
	LIU Hongjian
	XU Haitao
	ZHANG Qingguang

Cite this article:

JIA Teng,GU Xiaojie,LIU Hongjian, et al. Postoperative adjuvant chemotherapy for stage IB non-small-cell lung cancer:A systematic review and meta-analysis[J]. 滨州医学院学报, 2019, 42(4): 281-284.

URL:

http://manu58.magtech.com.cn/Jwk_bzyxy/EN/10.19739/j.cnki.issn1001-9510.2019.04.013 OR http://manu58.magtech.com.cn/Jwk_bzyxy/EN/Y2019/V42/I4/281

[1] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013 [J]. CA Cancer J Clin, 2013, 63(1):11-30.
[2] Martini N, Rusch V W, Bains M S, et al. Factors influencing ten-year survival in resected stages I to IIIa non-small cell lung cancer [J]. J Thorac Cardiovasc Surg, 1999, 117(1):32-36.
[3] Douillard J Y, Rosell R, Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association ): a randomised controlled trial [J]. Lancet Oncol, 2006, 7(9):719-727.
[4] Pignon J P, Tribodet H, Scagliotti G V, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group [J]. J Clin Oncol, 2008, 26(21):3552-3559.
[5] Strauss G M, Herndon J E, 2nd, Maddaus M A, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups [J]. J Clin Oncol, 2008, 26(31):5043-5051.
[6] Dediu M, Ion O, Ion R, et al. Impact of adjuvant chemotherapy in stage IB non-small-cell lung cancer: an analysis of 112 consecutively treated patients [J]. J BUON, 2012, 17(2):317-322.
[7] Higgins J P, Altman D G, Gotzsche P C, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials [J]. BMJ , 2011, 343:d5928.
[8] Higgins J P, Thompson S G, Deeks J J, et al. Measuring inconsistency in meta-analyses [J]. BMJ, 2003, 327(7414):557-560.
[9] Dias S, Sutton A J, Welton N J, et al. Evidence synthesis for decision making 3: heterogeneity--subgroups, meta-regression, bias, and bias-adjustment [J]. Med Decis Making, 2013, 33(5):618-640.
[10] Mineo T C, Ambrogi V, Corsaro V, et al. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer [J]. Eur J Cardiothorac Surg, 2001, 20(2):378-384.
[11] Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung [J]. N Engl J Med, 2004, 350(17):1713-1721.
[12] Roselli M, Mariotti S, Ferroni P, et al. Postsurgical chemotherapy in stage IB nonsmall cell lung cancer: Long-term survival in a randomized study [J]. Int J Cancer, 2006, 119(4):955-960.
[13] Butts C A, Ding K, Seymour L, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II non-small-cell lung cancer: updated survival analysis of JBR-10 [J]. J Clin Oncol, 2010, 28(1):29-34.
[14] Matthews M J, Kanhouwa S, Pickren J, et al. Frequency of residual and metastatic tumor in patients undergoing curative surgical resection for lung cancer [J]. Cancer Chemother Rep, 1973, 4(2):63-67.
[15] Niiranen A, Niitamo-Korhonen S, Kouri M, et al. Adjuvant chemotherapy after radical surgery for non-small-cell lung cancer: a randomized study [J]. J Clin Oncol, 1992, 10(12):1927-1932.
[16] Mineo T C, Ambrogi V, Corsaro V, et al. Postoperative adjuvant therapy for stage IB non-small-cell lung cancer [J]. Eur J Cardiothorac Surg, 2001, 20(2):378-384.ADDINEN.REFLIST